The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kriger A.G.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Berelavichus S.V.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Poliakov I.S.

Institut khirurgii im. A.V. Vishnevskogo Minzdrava RF, Moskva

Varava A.B.

Vishnevsky National Medical Research Center of Surgery of Ministry of Health of Russia, Moscow, Russia

Son A.I.

A.V. Vishnevskiy Institute of Surgery, Health Ministry of the Russian Federation, Moscow

Akhmedov B.G.

Department of Orthopedics and Arthrology of A.V. Vishnevsky Institute of Surgery, Health Ministry of Russia, Moscow, Russia

Galchina Yu.S.

Vishnevsky Institute of Surgery, Moscow, Russia

Pelvic plexiform neurofibroma in Recklinghausen disease

Authors:

Kriger A.G., Berelavichus S.V., Poliakov I.S., Varava A.B., Son A.I., Akhmedov B.G., Galchina Yu.S.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2017;(3): 90‑93

DOI: 10.17116/hirurgia2017390-93

Views: 2508

Downloaded: 48

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Kriger AG, Berelavichus SV, Poliakov IS, Varava AB, Son AI, Akhmedov BG, Galchina YuS. Pelvic plexiform neurofibroma in Recklinghausen disease. Pirogov Russian Journal of Surgery. 2017;(3):90‑93. (In Russ.)
https://doi.org/10.17116/hirurgia2017390-93

Подписка 2025 (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Close metadata

Keywords:

pelvic plexiform neurofibroma
Recklinghausen disease

Authors:

Kriger A.G.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Berelavichus S.V.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Poliakov I.S.

Institut khirurgii im. A.V. Vishnevskogo Minzdrava RF, Moskva

Varava A.B.

Vishnevsky National Medical Research Center of Surgery of Ministry of Health of Russia, Moscow, Russia

Son A.I.

A.V. Vishnevskiy Institute of Surgery, Health Ministry of the Russian Federation, Moscow

Akhmedov B.G.

Department of Orthopedics and Arthrology of A.V. Vishnevsky Institute of Surgery, Health Ministry of Russia, Moscow, Russia

Galchina Yu.S.

Vishnevsky Institute of Surgery, Moscow, Russia

List of references:

  1. Demestre M, Herzberg J, Holtkamp N, Hagel C, Reuss D, Friedrich RE, Kluwe L, Von Deimling A, Mautner VF, Kurtz A. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol. 2010;98:11-19. doi:10.1007/s11060-009-0049-4
  2. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311-314.
  3. Jakacki RI, Dombi E, Potter DM, Goldman S, Allen JC, Pollack IF, Widemann BC. Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology. 2011;76:265-272. doi:10.1212/WNL.0b013e318207b031
  4. Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell. 2009;4:453-463. doi:10.1016/j.stem.2009.03.017
  5. McCaughan JA, Holloway SM, Davidson R, Lam WW. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet. 2007;44:463-466. doi:10.1136/jmg.2006.048140
  6. von Recklinghausen, F. Uber die Multiplen Fibrome der Haut und ihre Beziehung zu Multiplen Neuromen. Berlin: August Hirschwald; 1882.
  7. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006;24:507-516. doi:10.1200/JCO.2005.03.8638
  8. Wu J, Dombi E, Jousma E, Scott Dunn R, Lindquist D, Schnell BM, Kim MO, Kim A, Widemann BC, Cripe TP, Ratner N. Preclincial testing of Sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer. 2011. doi:10.1002/pbc.23015
  9. Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y, Zhang S, Yang Y, Vakili ST, Yu M, Burns D, Robertson K, Hutchins G, Parada LF, Clapp DW. Nf1-dependent tumors require a microenvironment containing Nf1+/– and c-kit-dependent bone marrow. Cell. 2008;135:437-448. doi:10.1016/j.cell.2008.08.041

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.